BioPharma « Terug naar discussie overzicht

HIV; waarom lager?

1.470 Posts, Pagina: « 1 2 3 4 5 6 ... 68 69 70 71 72 73 74 » | Laatste

Omlaag ↓

[verwijderd] 26 oktober 2009 15:41

Is wel heel leuk, maar kan niets vinden. Wel met heel weinig stukjes.

gustaaf1e 26 oktober 2009 21:41

's kijken of ie blijft bewegen.
Tijdje geleden.
G

gustaaf1e 27 oktober 2009 18:54

Hij blijft in beweging...
G

[verwijderd] 27 oktober 2009 19:02

erg laag volume,dat is jammer

[verwijderd] 5 november 2009 16:05

heb toch de indruk dat er wat speelt bij cbmc de koers kruipt langzaam om hoog de laatste dagen

[verwijderd] 5 november 2009 19:47

Vandaag min 43,75%

AT

[verwijderd] 5 november 2009 20:06

ja zag het liep eerst mooi op ,
toen een paar grote dumps

opgezet denk ik om de aandeeltjes te lozen

[verwijderd] 5 november 2010 18:49

5 nov een jaar later
niks gebeurd

[verwijderd] 5 november 2010 18:58

Zo zijn er meer vlielander, triest maar waar, ik heb deze ook nog gehad, wel mooi dat je precies een jaar later eraan denkt hier te posten.

[verwijderd] 8 november 2010 21:23

Hee Nieuws!!!!!!!!!

Calypte Biomedical Awarded Therapeutic Discovery Project Grant
Calypte Biomedical Awarded Therapeutic Discovery Project Grant
Nov. 8, 2010 (GlobeNewswire) --

PORTLAND, Ore., Nov. 8, 2010 (GLOBE NEWSWIRE) -- Calypte Biomedical Corporation (Pink Sheets:CBMC), the developer, manufacturer and marketer of the Aware™ HIV-1/2 OMT (oral fluid) HIV test, announced today that it has been awarded a tax credit of $244,479 under U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

The QTDP tax credit is provided under the new section 48D of the Internal Revenue Code, enacted as part of the Patient Protection and Affordable Care Act of 2010. The credit is targeted to therapeutic discovery projects that show a reasonable potential to prevent, diagnose, and treat acute and chronic diseases. Allocation of the credit also takes into consideration which projects show the greatest potential to create and sustain high-quality, high-paying U.S. jobs and to advance U.S. competitiveness in life sciences.

"I am pleased that Calypte has been recognized by this program for having the potential to significantly improve HIV testing and early diagnosis," said Adel Karas, Chairman and CEO of Calypte.

A leader in HIV diagnostics, Calypte intends to bring to the US market a rapid test for HIV-1/2 using oral fluid instead of blood. Rapid testing results in higher rates of linkage to care than laboratory testing and is widely preferred by patients, while oral fluid testing is less invasive, cheaper and safer than blood tests. Although all reactive rapid test results must be confirmed by laboratory testing, algorithms based on multiple rapid tests have been successfully used in other countries to provide a diagnosis which allows immediate initiation of treatment. Up to half of all clients do not receive their laboratory results, and infected persons who are unaware of their status are not only at increased personal risk through lack of treatment, but are also 3-4 times more likely to transmit HIV than individuals who are aware that they are HIV-positive. Calypte therefore believes that rapid oral fluid testing offers dramatic potential for improvement in HIV medicine. Field trials of Calypte's second generation oral fluid rapid test are underway, in preparation for a US FDA clinical trial in 2011.

"Calypte exemplifies the cutting-edge, efficient use of resources that is possible in Oregon," said Congressman David Wu, who represents the Portland area in the U.S. House of Representatives. "By funding research projects that can change the course of infectious diseases like HIV, the federal government is helping create jobs and drive economic growth through innovation."

About Calypte Biomedical Corporation:

Calypte Biomedical Corporation develops in vitro testing products to improve the diagnosis of Human Immunodeficiency Virus (HIV) infection and other sexually transmitted and chronic diseases. Calypte's product line includes both point-of-care rapid tests and an EIA based incidence test.

Founded in 1988, Calypte is a pioneer in non-blood-based HIV antibody testing. Calypte is the only company to have earned FDA approval for a urine-based HIV-1 antibody-screening test and supplemental Western blot. Today, Calypte's Aware™ family of rapid oral fluid and blood based HIV tests offers flexible testing of HIV 1 and HIV 2 in a non-laboratory setting.

The Calypte Biomedical Corporation logo is available at www.globenewswire.com/newsroom/prs/?p...

vr gr willem.

[verwijderd] 16 maart 2011 17:49

er zit beweging in,we wachten af wat er staat te gebeuren

[verwijderd] 16 maart 2011 18:20

www.nasdaq.com/aspx/company-news-stor...

hier is waarom

gustaaf1e 16 maart 2011 21:25

Vlielander,
Ik had 't gezien.
Er is sindsdien i.i.g beweging.
Na zo'n lange stilte blijkt het bedrijf nog steeds springlevend.
G

[verwijderd] 16 maart 2011 21:37

misschien wordt het ooit nog wat,laten we het maar hopen

[verwijderd] 18 maart 2011 16:56

in de VS zijn ze positief.

www.barchart.com/opinions/stocks/CBMC

[verwijderd] 18 maart 2011 22:06

en weer 28% in de plus
geleidelijk steeds hoger

www.barchart.com/quotes/stocks/CBMC

gustaaf1e 19 maart 2011 10:54

Gezien de zgn "tax credit" gelooft men ook op goevernementeel niveau in het bedrijf. Daarnaast nog het pb met de aankondiging van de clinical trial voor FDA goedkeuring en de 100% accurancy resultaten.
Dat verklaart de opbloeiende handel in het aandeel.
G

[verwijderd] 21 maart 2011 13:39

van Yahoo geplukt,

Some of you do not know aht you are talking about when you say 667 M market cap at 667 M share impossible. Look at HTWR at 42B market cap for LVAD at only 200 M market for LVAD. Thw market on HIV diagnostic is 3.5 B and growing. Speculatin that CBMC can take 5-10% of that in the future (or a company that buys CBMC) is certainly within possibility. In fact a 1$ per share CBMC per speculation is more reasobale thant an $84 per share HTWR at a 42 B market cap in a 200 M doallar market potential. HTRW went from .25 to $27 in one day a few years ago, so CBMC can fo .01-.03 up to a dollar w/in a year if not much much sooner. Roth and Stark recently purchased 47M shares of CBMc this past Dec at .03. I dont see a venture group spending $150K on a .006 stock (pps in Dec) unless they know nsomething and see a huge return on the risk. Rating :
(No ratings)Rate it:

[verwijderd] 21 maart 2011 15:04

zit duidelijk in de lift

alweer 18% plus

[verwijderd] 16 oktober 2011 14:43

misschien dat dit nieuws wat beweging zet in de koers,

PORTLAND, Ore., Oct. 14, 2011 (GLOBE NEWSWIRE) -- Calypte Biomedical Corporation (OTCBB:CBMC.PK - News), a developer, manufacturer and marketer of HIV diagnostic tests, today announced that it has entered into a memorandum of understanding (MoU) with a private investor to secure funding needed to complete the FDA approval procedures for the new product AWARE(TM) 2. The MoU contemplates an initial investment of at least $1,000,000 through 2012, contingent upon the Company following an agreed upon budget plan, and potentially up to $4,000,000 from additional investors.

As announced on March 2, 2011, Calypte successfully completed internal trials on its new AWARE(TM) 2 HIV-1/2 oral fluid rapid test, which showed an accuracy of 100%. Based on these promising results, Calypte has contacted the FDA and started the process to conduct clinical trials.

"We are extremely pleased that we were able to secure this investment," stated Adel Karas, CEO of Calypte. "It shows continued support and belief in Calypte Biomedical, and was a critical milestone allowing us to move forward with the FDA clinical trials of our AWARE(TM) 2 product that has the potential to significantly improve HIV testing and early diagnosis."

1.470 Posts, Pagina: « 1 2 3 4 5 6 ... 68 69 70 71 72 73 74 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 899,06 +9,37 +1,05% 17:30


Germany40^	22.678,40	+1,57%
BEL 20	4.379,55	+1,93%
Europe50^	5.358,51	+0,92%
US30^	41.417,90	-0,04%
Nasd100^	19.669,30	+1,51%
US500^	5.614,04	+0,78%
Japan225^	37.163,40	+1,70%
Gold spot	2.938,60	+0,74%
EUR/USD	1,0914	-0,02%
WTI	67,72	+1,74%